COVID-19 “Rebound” associated with nirmatrelvir/ritonavir pre-hospital therapy

Coulson, J.M., Adams, A., Gray, L.A. and Evans, A. 2022. COVID-19 “Rebound” associated with nirmatrelvir/ritonavir pre-hospital therapy. Journal of Infection 85 (4) , pp. 436-480. 10.1016/j.jinf.2022.06.011

Preview

PDF - Published Version Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (7MB) | Preview

Abstract

The efficacy of nirmatrelvir/ritonavir, an orally active chymotrypsin-like cysteine protease inhibitor in combination with a CYP3A4 inhibitor, in reducing hospitalisation or death from COVID-19 infection has been demonstrated in a high-risk adult population.1 Treatment within five days of COVID-19 symptoms was associated with a progressive reduction in viral load compared to the placebo arm; the duration of COVID-symptoms and changes in symptom severity were not reported.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Additional Information:	License information from Publisher: LICENSE 1: URL: http://creativecommons.org/licenses/by-nc-nd/4.0/, Start Date: 2023-09-06
Publisher:	British Infection Association
ISSN:	0163-4453
Date of First Compliant Deposit:	21 October 2022
Date of Acceptance:	13 June 2022
Last Modified:	06 Sep 2023 14:44
URI:	https://orca.cardiff.ac.uk/id/eprint/152439

Citation Data

Cited 4 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item